Structural Heart Devices Market (2026-2036)
The global structural heart devices market was valued at USD 16.7 billion in 2026. This market is expected to reach USD 48.2 billion by 2036, growing at a CAGR of 11.2% during the forecast period 2026–2036.
- Published
- Jun 2026
- Pages
- 246
- Format
- PDF + Excel
- Report ID
- MRHC - 1042009
- Base year
- 2025
- 2026 · ESTIMATED
- $16.70B
- 2036
- $48.20B
- CAGR 2026–2036
- 11.2%
2025 baseline · 2026–2036 forecast at 11.2% CAGR · hover a bar for the value
Key highlights
The global structural heart devices market is projected to reach USD 48.2 billion by 2036.
The market is expected to grow at a CAGR of 11.2% during the forecast period 2026–2036.
The global structural heart devices market is estimated at USD 16.7 billion in 2026.
TAVR/TAVI remains the largest product segment, accounting for over 50% of total market revenue in 2026.
North America is expected to dominate the market with the largest share in 2026, supported by high clinical adoption and favorable reimbursement policies.
Asia-Pacific is projected to witness the fastest growth during the forecast period, fueled by a rising geriatric population and improving healthcare access.
LAA closure devices are identified as one of the fastest-growing sub-segments, driven by the increasing incidence of atrial fibrillation.
Valvular heart disease affects approximately 13% of individuals aged 75 and older, providing a strong long-term driver for the market.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 16.70 billion |
| Market Size (2036) | USD 48.20 billion |
| CAGR (2026–2036) | 11.2% |
| Format | PDF, Excel & Cloud Portal · 246 pages |
| Segments Covered | By Product: Heart Valve Devices, Annuloplasty Rings, Occluders and Closure Devices, Others · By Indication: Valvular Heart Disease, Cardiomyopathy, Congenital Heart Defects, Others · By End User |
| Key Companies | Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, Terumo Corporation |
Report overview
Segments covered: product, indication, end user.
The global structural heart devices market is a cornerstone of the modern cardiovascular medical technology industry, focusing on the development and deployment of innovative devices to treat defects and abnormalities in the heart's valves and chambers. This market covers a wide range of life-saving technologies, including transcatheter heart valves, annuloplasty rings, and septal occluders. The primary focus is on addressing conditions such as aortic stenosis, mitral regurgitation, and congenital heart defects through minimally invasive or percutaneous approaches. The growth of this market is mainly driven by the global aging population, the increasing prevalence of valvular heart disease, and the clinical shift from high-risk open-heart surgery toward safer, transcatheter-based therapies.
Transcatheter Aortic Valve Replacement (TAVR) remains the dominant segment within the market, having revolutionized the treatment of severe aortic stenosis. As of 2025, TAVR has become the dominant form of aortic valve replacement in the United States, with estimates suggesting over two-thirds of procedures performed via transcatheter routes. This trend is expected to continue as FDA-approved indications expand from high-risk to low-risk patient populations (FDA approved low-risk TAVR in 2019. Furthermore, the market is witnessing a surge in innovation for mitral and tricuspid valve therapies (TMVR and TTVR), which represent the next major frontier in structural heart intervention. The prevalence of valvular heart disease increases significantly with age, affecting around 10-13% of individuals aged 75-79 and 14-15% of those aged 80-85 with moderate or greater disease (12.5% overall for 75+), creating a strong demand for durable and effective structural heart solutions.
Despite the rapid technological advancements, the structural heart devices market faces restraints, including the high cost of transcatheter procedures and the stringent regulatory pathways required for new device clearances. The financial burden on healthcare systems for these high-value devices can be a barrier to adoption in price-sensitive regions. Additionally, while minimally invasive, these procedures still carry risks of conduction disturbances and paravalvular leaks, necessitating continuous refinement in device design and delivery systems. However, the emergence of Left Atrial Appendage (LAA) closure devices as an alternative to long-term anticoagulation for stroke prevention in atrial fibrillation patients presents a substantial growth opportunity, with this segment projected to witness some of the highest growth rates in the industry.
Report infographic
Market dynamics
7 factors across 5 forcesThe major driver for the structural
heart devices market is the aging global population and the subsequent increase in the prevalence of age-related heart conditions. Aortic stenosis and mitral regurgitation are significantly more common in older adults, necessitating the use of structural heart devices for repair or replacement. The American Heart Association (AHA) has highlighted that as the global population continues to age, the burden of valvular heart disease will grow, creating a sustained demand for innovative interventional therapies.
Another key driver is the expansion
of clinical indications for transcatheter aortic valve replacement (TAVR). Initially reserved for high-risk surgical patients, TAVR is now increasingly being used for intermediate and low-risk patients based on robust clinical trial data demonstrating its safety and efficacy. This expansion has significantly increased the target patient population for structural heart devices. Furthermore, the continuous improvement in device delivery systems, which are becoming smaller and more flexible, is allowing for safer procedures and broader clinical adoption.
Table of contents
11 chapters · 109 sections · 246 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product | Heart Valve Devices | — |
By Product
- Heart Valve Devices to Hold Largest Share
- The heart valve devices segment is expected to hold the largest share of the market.
- This dominance is due to the established clinical success of TAVR and the high unit cost of transcatheter valves.
- Heart valve devices are the primary revenue generator for major players in the structural heart market, driven by the high volume of aortic valve replacement procedures.
- The occluders and closure devices market is projected to register a significant CAGR during the forecast period.
- This growth is driven by the rapid expansion of the LAA closure market and the increasing use of septal occluders for treating congenital heart defects like patent foramen ovale (PFO) and atrial septal defect (ASD).
- The shift away from long-term blood thinners is a major driver for this segment.
Geographic analysis
North America
Largest shareNorth America is expected to dominate the global structural heart devices market in 2026, primarily due to its advanced healthcare infrastructure, high clinical adoption of new technologies, and favorable reimbursement policies. The U.S. is the leading market for structural heart innovation, with a robust ecosystem of technology providers and research institutions. The presence of major industry players like Edwards Lifesciences and Abbott is a key driver. The key companies operating in the North American market are Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific.
Asia-Pacific
Fastest growthThe Asia-Pacific structural heart devices market is projected to witness the fastest growth during the forecast period. This is driven by rapid digitalization in healthcare, increasing investments in medical technology in China and India, and a rising geriatric population. The region's large population and the increasing adoption of advanced medical technologies are driving the demand for scalable structural heart solutions. The key companies operating in the Asia-Pacific market are Terumo, Lepu Medical, Microport, and various emerging medical technology specialists in the region.
Competitive landscape
- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corporation
- Johnson & Johnson
- Terumo Corporation
Frequently asked questions
The market is projected to reach USD 48.2 billion by 2036, growing at a CAGR of 11.2% from 2026 to 2036.
Cite this report
Meticulous Research. (2026). Structural Heart Devices Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042009). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/structural-heart-devices-market-6692